Plus Therapeutics (NASDAQ: PSTV) stock is surging premarket following the announcement of an agreement with RadioMedix for the commercial production of the company’s radiopharmaceuticals.
The agreement will see RadioMedix produce a cGMP drug product that meets all the US Food and Drug Administration (FDA). In addition, the partnership further ensures the commercial supply chain for 186RNL with PSTV saying it will extend to future products under the RNL platform.
186RNL is being developed to treat recurrent GBM, leptomeningeal metastases, and pediatric brain cancer.
“RadioMedix is a global leader in the development and production of GMP radiopharmaceutical products,” said Marc Hedrick, President and CEO of Plus Therapeutics.
“This strategic partnership substantially supports our efforts to have fully compliant 186RNL available by mid-2022 for a potential Phase 2/3 clinical study in adults with recurrent glioblastoma (GBM).”
Plus Therapeutics stock is trading at $2.28 premarket after rising 20%.
Should You Invest in Plus Therapeutics Shares?
One of the most frequently asked questions we receive is, “what stocks are best to buy right now?” It's a wide-ranging question, but one that we have answered… Our AskTraders stock analysts regularly review the market and compile a list of which companies you should be adding to your portfolio, including short and longer-term positions. Here are the best stocks to buy right now
